Compare Mesoblast Limited (MESO) vs Warner Music Group Corp (WMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Warner Music Group Corp — how do they compare? Mesoblast Limited trades at $16.32 (market cap $2.17B), while Warner Music Group Corp trades at $28.02 (market cap $14.64B). The key difference: Warner Music Group Corp is far larger — about 6.7× Mesoblast Limited's market cap, and Warner Music Group Corp pays a 2.71% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | WMG | |
|---|---|---|
Market Cap | $2.17B | $14.64B |
Sector | Technology | Media |
52-Week High | $20.96 | $34.72 |
52-Week Low | $12.88 | $23.65 |
Enterprise Value | $2.17B | $18.84B |
Dividend Yield | — | 2.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Warner Music Group (WMG) trades at $28.08, down 0.88% on the day, with a bearish technical signal and mixed earnings history. Revenue growth is steady, reaching $6.71B in 2025, but net income margin has declined to 5.44%. Recent developments include a strategic renewal with NetEase Cloud Music and the acquisition of AI startup Sureel AI, enhancing IP monetization capabilities in the evolving music industry.
The stock offers a 44% upside to the consensus price target of $40.40, supported by strong analyst buy ratings (66.66%), but faces risks from competitive pressures and margin compression. Investors should weigh the high P/E ratio of 33.73 against growth initiatives and cash flow improvements projected for 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Warner Music Group Corp
Warner Music Group is the third largest of the three major global record labels, with Vivendi's Universal Music in first and Sony Music in second. Warner's larger segment, recorded music, consists of iconic labels like Atlantic Records, Warner Records, and Parlophone Records and popular artists such as Ed Sheeran, Cardi B, Dua Lipa, and Blake Shelton. Warner Chappell, the firm's publishing arm, is the home to over 65,000 composers and songwriters with over a million copyrights represented. Warner is controlled by Access Industries, which owns an 84% economic interest and 99% of voting rights.
Read more on WMG →
